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Abstract The objective of this review is to discuss
emerging concepts in pelvic organ prolapse, in particular,
“What is cure?” In a post-trial data analysis of the CARE
(Colpopexy and Urinary Reduction Efforts) trial, treatment
success varied tremendously depending on the definition
used (19.2%–97.2%). Definitions that included the absence
of vaginal bulge symptoms had the strongest relationships
with the patients’ assessment of overall improvement and
treatment success. As demonstrated by this study, there are
several challenges in defining cure in prolapse surgery.
Additionally, the symptoms of prolapse are variable. The
degree of prolapse does not correlate directly with
symptoms. There are many surgical approaches to pelvic
organ prolapse. Multiple ways to quantify prolapse are
used. There is a lack of standardized definition of cure. The
data on prolapse surgery outcomes are heterogeneous. The
goal of surgical repair is to return the pelvic organs to their
original anatomic positions. Ideally, we have four main
goals: no anatomic prolapse, no functional symptoms,
patient satisfaction, and the avoidance of complications.
The impact of transvaginal mesh requires thoughtful
investigation. The driving force should be patient symptoms
in defining cure of prolapse.
Keywords Pelvic organ prolapse . Female pelvic floor
dysfunction . Surgical outcomes . Vaginal mesh . Quality of
life . Cystocele . Translabial ultrasound
Introduction
Pelvic organ prolapse is a common condition in older
women, the largest growing demographic in the United
States. Pelvic prolapse affects up to 50% of women [1].
Symptomatic pelvic organ prolapse often requires surgery.
Women have an 11% lifetime risk of needing surgery for
pelvic floor disorders and a 29% reoperation risk for
incontinence and prolapse [2]. In 1997, more than
225,000 inpatient surgical procedures for pelvic organ
prolapse were undertaken in the United States, at an
estimated cost of more than $1 billion [3, 4]. The impact
of pelvic organ prolapse is great on both an individual and a
societal level. A great deal about this complex disease has
been learned, yet there is much more to learn in this area.
The objective of this article is to discuss emerging concepts
in pelvic organ prolapse, in particular, “What is cure?”
Defining Success in Prolapse Surgery
In 2009, Matt Barber, in collaboration with the Pelvic Floor
Disorders Network [5••], wrote, “Defining Success after
Surgery for Pelvic Organ Prolapse” a post-trial data
analysis of data from 322 women who completed 2-year
follow-up in the CARE (Colpopexy and Urinary Reduction
Efforts) trial, a randomized trial to evaluate if abdominal
sacrocolpopexy with or without Burch colposuspension
improves urinary stress incontinence in women without
preoperative SUI. By using the pelvic organ prolapse
quantification (POP-Q) assessment, the Pelvic Floor Distress
Inventory responses, data on retreatment, and patients’
subjective ratings of overall treatment success and global
improvement, 18 different definitions of surgical success after
surgery for stage 2 to 4 pelvic organ prolapse were created.
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Treatment success varied tremendously depending on the
definition used (19.2%–97.2%), raising an important issue in
the management of pelvic organ prolapse: what is cure?
No generally accepted definition for success after pelvic
prolapse surgery exists. The 2001 National Institutes of
Health (NIH) Workshop on Standardization of Terminology
defined “optimal” anatomic outcome as stage 0 and
“satisfactory” anatomic outcome as stage 1 [6]. Based on
a multicenter observational study of the distribution of
pelvic organ prolapse in women presenting for annual
gynecologic exams, the NIH definition likely is too strict.
The prevalence of pelvic organ prolapse quantification
stages was 24% (stage 0), 38% (stage 1), 35% (stage 2),
and 2% (stage 3) [6]. Of women presenting for annual
exams, 75% would not meet “optimal” definition and 40%
would not meet the “satisfactory” anatomic outcome
definition. According to the Barber et al. [5••] study,
definitions that included the absence of vaginal bulge
symptoms had the strongest relationships with the patients’
assessment of overall improvement and treatment success.
Additionally, definitions based on anatomic success had
weak or absent correlation with patient perception of
outcome [5••]. Given this finding, definitions for success
after prolapse surgery should include absence of vaginal
bulge symptoms.
Outcomes in Prolapse Surgery
There are four main outcomes to consider in prolapse
surgery, illustrated by four overlapping circles, forming a
Venn diagram (see Fig. 1):
1. Anatomy of the anterior vaginal wall, vaginal vault,
posterior vaginal wall, and perineum;
2. Function of the bladder and colon, and sexual function;
3. Patient satisfaction, bother, and impact on health-
related quality of life; and
4. Avoidance of complications.
Interestingly, the Barber [5••] article highlights that
treating anatomy is not the most important factor for
patients’ perception of success. Rather, the absence or
presence of symptoms drives patients’ perception of
success. This data also confirms that there often is a
disconnection between anatomy and symptoms. Vaginal
prolapse within 1 cm from the hymen was found in 58% of
women, yet 92% of women felt subjective cure. Most
bowel, bladder, and pelvic symptoms thought to be
associated with pelvic organ prolapse have weak to
moderate correlations with the severity of prolapse [7–10].
The symptom that most correlates with advanced prolapse
is the presence of a vaginal bulge that can be seen or felt
[10, 11]. Additionally, the hymen is an important anatomic
cutoff point that correlates to patient symptoms of vaginal
bulge [12, 13].
Ideally, a clinically meaningful definition of surgical
success should demonstrate improved symptom-bother
scores and health-related quality of life when compared to
treatment failures. Vaginal bulge symptoms were found in
90% of women once the leading edge of the vagina is
beyond the hymen upon straining, and patients are pleased
with their surgical outcome if their vaginal bulge symptoms
are eliminated [14••]. Patient-centered goals for pelvic floor
dysfunction also have been described, which broadly include
four types of goals: symptom relief, activity, self-image, and
general health [15].
Is the goal of prolapse surgery to produce perfect
anatomy or to cure symptoms and provide better quality
of life? Should we operate only for cure of the anatomic
changes or only if the patient has symptoms regardless the
degree of prolapse? The incidence of de novo urinary
urgency after anatomic correction has been shown to be
5%–25% [16, 17] and the incidence of de novo dyspareunia
is variable, but 15%–25% without mesh, and as high as
63% with a mesh augmented repair [18, 19]. Surgical
intervention is not without costs and complications.
Therefore, the lack of standardized definitions of the
disease and outcomes in pelvic organ prolapse is a critical
area for our field to address.
Grading and Staging of Prolapse
Defining cure is not standardized. One contributing factor is
that multiple prolapse grading and staging systems are
used. The POP-Q is considered the gold standard, but has
limitations. The advantages of the POP-Q are that it is
quantitative, has fixed reference points, and is validated.Fig. 1 Venn diagram of outcomes of prolapse surgery
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The disadvantages included that it is cumbersome, variable
by patient position and examination technique, and poorly
utilized. Only 40% of International Continence Society/
American Urogynecologic Society members use the POP-Q
in their clinical practice [20]. The two most commonly used
systems in peer-reviewed urology and gynecology literature
were the POP-Q (22.6%), and the Baden-Walker (BW)
system (19.8%) [21]. The BW system is simple and well
utilized, but the disadvantage is that it relates organ-specific
instead of compartmental defects. Each component (urethra,
cystocele, uterus, rectocele, enterocele, perineum) are
graded from 0 to 4. To address the need for a clinically
relevant evaluation of prolapse grade and stage, the POP-Q-
Baden-Walker (POPQ-BW) was developed [30]. The
POPQ-BW uses the advantages of the POP-Q combined
with the ease of use of the BW system. Only three simple
measurements (genital hiatus, perineal body, and total
vaginal length) are required. The degree of descent of each
POP-Q point (Aa, Ba, C, Ap, Bp, D) is reported using the
BW scale (0–4). The POPQ-BW provides a reliable, fast,
reproducible evaluation of vaginal prolapse. This hybrid
system perhaps may increase utilization of a grading and
staging system for prolapse. The “eyeball” POP-Q, in
which the measurements are estimated, also is highly
correlated with the traditional POP-Q among examined
patients who routinely perform the POP-Q [23].
Patient-reported Global Improvement
Women with prolapse seek treatment to improve their
quality of life. Women with prolapse have decreased body
image and overall quality of life [22, 24]. The Patient
Global Improvement Inventory (PGII) scale is a useful tool
in assessing patient improvement after surgery with one
simple question, “Check the number that best describes
how your post-operative condition is now, compared with
how it was before you had the surgery: very much better,
much better, a little better, no change, a little worse, much
worse, very much worse.” There was no validated global
outcome assessment index in prolapse research until
recently. The PGII has been validated as a measurement
of global improvement after prolapse surgery [25•], and
likely will be well utilized in future prolapse outcomes
research.
The Use of Mesh in Prolapse Surgery
The surgical treatment of pelvic organ prolapse from a
vaginal approach experienced a surge in the use of graft
materials. The use of mesh in vaginal prolapse surgery
stems from a desire for improved anatomic outcomes.
Interestingly, vaginal mesh kits for prolapse repair were given
US Food and Drug Administration (FDA) 510(k) premarket
approval by demonstrating “equivalency” to existing devices.
Mesh augmented prolapse surgery demonstrates better ana-
tomic results but has a higher risk of complications (0%–23%)
[26••, 27]. However, complications from vaginally placed
mesh are likely underreported. The full range of complica-
tions is also difficult to quantify. Using the Clavien-Dindo
Classification system [28], mesh complications that require a
subsequent procedure under anesthesia falls under class IIIb.
However, the degree of bother and impact on quality of life
after a complication of vaginally placed mesh is difficult to
fully evaluate. Mesh complications range from minor to
major, and can include vaginal wall exposure, bladder and
urethral mesh erosion, vaginal pain, vaginal wall induration,
dyspareunia, leg pain, difficulty walking, and temporary or
permanent neuropathy. Age-related changes of the vagina
contribute to the development of these complications over
time. An additional criticism of most mesh prolapse kits is
that some do not correct vault prolapse.
Use of Translabial Ultrasound
The use of translabial ultrasound increasingly has become a
helpful tool for diagnosis and preoperative planning of
mesh complications [29]. Mesh is not detectable with X-ray
or CT. Ultrasound is superior to MRI in detecting mesh
implants. Translabial ultrasound can confirm the presence
and location of residual synthetic graft material (see Fig. 2a
and b). The technique involves patients in supine position
with knees flexed or in lithotomy, with the bladder
moderately filled. Coronal, sagittal, and axial views are
obtained with the 5–9 MHz-translabial, curvilinear (Philips
IU22; Philips Healthcare, Andover, MA) transducer placed
on the perineum near the introitus. A dynamic evaluation is
obtained with Cine image (real-time graphics on cine
playback) in the resting state, squeeze, valsalva, kegel,
and cough. Translabial ultrasound can assess the structure
of mesh and helps to correlate clinical findings. It does not
help to diagnose vaginal, bladder, or urethral erosion.
Further studies on evaluating the clinical use of translabial
ultrasound imaging are needed.
US Food and Drug Administration Black Box Warning
on Use of Mesh
The FDA issued a black box warning on the use of mesh in
October 2008, citing, “Most frequent complications included
erosion through vaginal epithelium, infection, pain, urinary
problems, and recurrence of prolapse and/or incontinence.”
The concept of learned intermediary doctrine shifts the
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liability of harm away from manufacturer and onto the
physician. Therefore, informed consent between physician
and patient when using mesh in any female pelvic reconstruc-
tive procedure is essential.
Do the Benefits of Mesh Outweigh the Risks?
The use of mesh has demonstrated a lower risk of prolapse
recurrence. However, the true impact and incidence of
complications is unknown. Open, laparoscopic, or robot-
assisted sacrocolpopexy has a much lower risk of mesh-
related complications compared to vaginal surgery. The use
of mesh in vaginal prolapse repair is up to the individual
surgeon and the patient. However, given the risks, the
selective use of mesh in vaginal prolapse repair likely is
warranted.
Cystocele Repair with Interlocking Permanent Suture:
an Alternative to Mesh
Grade 4 cystocele continues to be a challenge in pelvic
floor reconstruction. The traditional anterior colporrhaphy
has a high recurrence rate. Mesh-augmented cystocele
repairs have better anatomic results, but higher complication
rates. An alternative to mesh is the use of permanent sutures to
provide a net of support. A brief description of the new
procedure, Cystocele repair with interlocking permanent
suture is as follows: a vertical incision is made from the
bladder neck to the vaginal cuff and carried out laterally. 2-0
polypropylene sutures are used to incorporate the obturator
and perivesical fascia bilaterally for lateral support. Mattress
sutures of 2-0 polypropylene are placed to repair the central
defect. The lateral sutures then are interlocked with the central
ones (see Fig. 3). The sutures then are tied, thereby reducing
the cystocele and creating a supporting net. The vaginal wall
is excised asymmetrically and closed as a rotational flap.
Preliminary data show significant symptomatic improvement
and improved quality of life. The technique has been
modified to address early treatable complications, such as
incidences of exposed 2 to 3 mm of suture, which was
treated in office, and one case of ureteric obstruction, which
was treated endoscopically. The “CRISP” (Cystocele Repair
using Interlocking Sutures of Prolene) procedure is a
promising alternative to mesh repair. Long-term data on
outcomes is needed and forthcoming.
Fig. 3 Diagram of CRISP (cystocele repair using interlocking sutures
of Prolene [Ethicon, Somerville, NJ]) procedure
Fig. 2 a. Translabial ultrasound of anterior vaginal wall meshes in the
sagittal plane. b Translabial ultrasound demonstrating folded anterior
vaginal wall mesh
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Challenges in Curing Prolapse
There are several challenges in defining cure in prolapse
surgery. The symptoms of prolapse are variable. The degree
of prolapse does not correlate directly with symptoms.
There are many surgical approaches to pelvic organ
prolapse. Multiple ways to quantify prolapse are used.
There is a lack of standardized definition of cure. The data
on prolapse surgery outcomes are heterogeneous. Therefore,
the treatment of pelvic organ prolapse is challenging due in
part to the lack of correlation between anatomy and
symptoms, as well as to the lack of standardization of
outcome measures. We try to repair the position of the pelvic
organs to their original anatomic positions. Ideally, we have
four main goals: no anatomic prolapse, no functional
symptoms, patient satisfaction, and the avoidance of compli-
cations. What is most important is that the driving force in
defining cure of prolapse should be patient symptoms.
Conclusions
Defining success after prolapse surgery requires anatomy,
function, complication, and quality of life measures. The
impact of transvaginal mesh requires thoughtful investigation.
A thorough understanding of pelvic anatomy is required.
Critical analysis of surgical outcomes is necessary.
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